Abstract This study aims to systematically review, critically appraise and identify from the published literature, the most effective interventions to improve medication adherence in osteoporosis. A literature search using Medline, EMBASE, Cochrane library, and Cumulative Index to Nursing and Allied Health Literature was undertaken to identify prospective studies published between January 1, 1999 and June 30, 2012. We included studies on adult users of osteoporosis medications that tested a patient adherence intervention (e.g., patient education, intensified patient care, different dosing regimens) and reported quantitative results of adherence. The Delphi list was modified to assess the quality of studies. Of 113 articles identified, 20 studies fulfilled the inclusion criteria. The most frequent intervention was education (n = 11) followed by monitoring/supervision (n = 4), drug regimens (n = 2), drug regimens and patient support (n = 1), pharmacist intervention (n = 1), and electronic prescription (n = 1). Although patient education improved medication adherence in four studies, two large-scale randomized studies reported no benefits. Simplification of dosing regimens (with and without patient support program) was found to have a significant clinical impact on medication adherence and persistence. Monitoring/supervision showed no impact on medication persistence while electronic prescription and pharmacist intervention increased medication adherence or persistence. In conclusion, this review found that simplification of dosing regimens, decision aids, electronic prescription, or patient education may help to improve adherence or persistence to osteoporosis medications. We identified wide variation of quality of studies in the osteoporosis area. The efficacy of patient education was Osteoporos Int (2013) 24:2907-2918 DOI 10.1007/s00198-013-2364 variable across studies, while monitoring/supervision does not seem an effective way to enhance medication adherence or persistence.
Introduction
Sub-optimal adherence and persistence with appropriately prescribed medication are prevalent in osteoporosis. Several studies have demonstrated that between 50 and 75 % of patients who were prescribed anti-osteoporotic medications have discontinued their medications within 1 year [1] [2] [3] [4] [5] . Low medication adherence leads to lower gains in bone mineral density and higher fracture rates [6] , resulting in substantial clinical and economic burden [7, 8] . Approximately 50 % of the potential clinical benefits of osteoporosis medications may be lost due to poor adherence [7, 9] , and the cost-effectiveness of osteoporosis management is significantly affected by reduced medication adherence [10, 11] .
There are many strategies aimed at improving adherence and persistence with medications. However, evidence across multiple treatments for a diverse range of diseases suggests that the effectiveness of current methods is both variable and modest [12, 13] . With specific reference to osteoporosis, there have been several interventions and programs developed in recent years, probably in response to the increasing use of bisphosphonates, first introduced around 1990 [14] . This study aims to critically appraise the published literature on interventions to improve patient adherence and persistence with medications to treat osteoporosis and to determine the most effective interventions. A previous review [15] noted a lack of effective intervention in a small sample of eight studies. Since then, more interventions have been tested and published, and this review provides further examination of interventions to improve adherence and persistence in osteoporosis.
Methods

Search strategy
A literature search undertaken in accordance with the Preferred Reporting Items for Systematic Reviews and Metaanalyses guidelines (http://www.prisma-statement.org/) was carried out in Medline, EMBASE, Cochrane library, and Cumulative Index to Nursing and Allied Health Literature and using the following key words separated by Boolean operators: [osteoporosis, low bone density, bone fragility, fractures bone, bone demineralization, pathologic osteopenia, low bone mineral density, low bone mass, low bone turnover, low bone mass density OR bisphosphonates, diphosphonates, etidronic acid, clodronic acid, pamidronicate, risedronate acid, ibandronic acid, alendronate, calcium, colecalciferol, estrogens, hormone replacement therapy (HRT), raloxifene, vitamin D] AND [medication adherence, patient compliance, persistence, non-compliance, non-persistence, concordance, non-concordance], AND [interventions, clinical trial, experiment, RCT]. The search period was from January 1, 1999 to June 30, 2012 . We restricted our search to the last decade because as no adherence intervention for use in osteoporosis was identified before that period [15] . References of selected articles and of a prior review [15] were also searched.
Selection criteria
We included interventional studies of adult users of osteoporosis medications (not limited to bisphosphonates) or calcium and vitamin D supplements that tested any intervention for an improvement in adherence or persistence and reported quantitative measures of adherence and/or persistence. NonEnglish studies or observational studies were excluded.
Extracted information
Each paper was reviewed independently by two investigators (MH, MS, DH, PL, EM, or FGS) and disagreements were resolved by consensus. The extracted information included study design, type of intervention, other characteristics of intervention, measurement of adherence, persistence, outcomes, population, follow-up time, ethics approval, sample size, statistical analysis, results of the intervention effect, medication possession ratios or other adherence or persistence measures, adjustment for confounders, and clinical outcomes. Due to the heterogeneity in the methods of adherence measurement and of study outcomes, the analysis was focused on a qualitative assessment.
Quality criteria
The Delphi list [16] was modified to assess the quality of studies. The original checklist contains 17 domains and eight items, but elements to evaluate interventional behavioral studies were not included. Therefore, we added methodological items that were considered relevant for behavioral studies, and they included study design, type of intervention, measure of adherence, outcomes, population, follow-up time, ethics approval, sample size, statistical analysis, and results. We assigned a score of 1 if the study included the required item, otherwise zero. Therefore, the maximum score for an article that included all information related to study design, data collection, analysis, and interpretation of results was 30 ("Appendix 1"). Consistency of quality scoring was achieved by having at least two reviewers scoring each paper independently. Only few discrepancies became evident, and these were resolved by consensus.
Results
There were 113 articles identified, and a total of 20 studies [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] fulfilled the inclusion criteria (Fig. 1) . Literature reviews (n=15), research that lacked a medication adherence intervention (n=45), disease management (n=11), economic studies (n=8), descriptions of protocols (n=2), and four other were excluded (see "Appendix 2"). The most frequent intervention was education (n=11) followed by monitoring/supervision (n=4), simplification of dosing regimens (n=2), drug regimen combined with patient support (n=1), electronic prescriptions (n=1), and pharmacist intervention (n=1). Interventions were led by physicians (n=5), pharmacists (n=4), nurses (n=3), multidisciplinary teams (n=3), clinical personnel (n=3), health educators (n=1), and it was unknown in one study.
The characteristics of included studies are reported in Tables 1 and 2 . Eleven out of the 20 studies [21, 22, [28] [29] [30] [31] [32] [33] [34] [35] [36] were published since 2010. Fifteen studies were randomized controlled trials (RCT) [18, 20, 21, [24] [25] [26] [27] [29] [30] [31] [32] [33] [34] [35] [36] , and two were cross-over designs. Other studies were nonrandomized uncontrolled studies [17, 19, 22, 23, 28] . Most tested an educational program, but these varied substantially between studies [17, 19, [21] [22] [23] [24] 27, 28, 31, 35, 36] in the content and method of delivery, which included group-based, face-to-face, telehealth program, or telephone counseling and written information (letters, leaflets, brochures). In one study [28] , pharmacists led the intervention in decentralized clinical pharmacy-managed services. Patients included in the studies were mainly postmenopausal women with osteoporosis. In total, 14,662 patients were included in the studies: 9,420 in the intervention arm and 5,242 in the control arm, 64 % of which were from four trials of more than 1,000 patients per trial [20, 24, 25, 35] . Most studies reported ethics review approval, and the followup after conduct of the intervention ranged from 4 to 48 months. Table 2 presents primary outcomes, method of adherence measurement, statistical analysis, results, and quality score. All studies used adherence as primary outcome except one study [20] that only reported persistence and two studies where adherence was used as a secondary outcome (persistence being the primary outcome) [28, 36] . Eight studies reported both adherence and persistence data [18, [24] [25] [26] [30] [31] [32] 35] . Adherence definitions varied: Where an explicit cutoff was used to define adherence (e.g., >80 % of doses taken), this was applied to calculate the proportion of patients adhering to therapy at time T, proportion of patients taking their medicine correctly, and medication possession ratio. In other cases, patients were labeled as adherent without an explicit cutoff. Persistence was defined as the proportion of patients continuing treatments at a given follow-up time. Adherence and persistence outcome data were collected from prescription records (n=7), electronic monitoring (n=5), self-report questionnaire (n=6), and two did not provide the information [17, 33] . None of the studies examined adherence or persistence in relation to clinical outcomes. Eight studies had adjustments for some potential confounders [20, 21, 25, 26, 30, 31, 34, 35] which may not be necessary in properly randomized trials where confounding variables would presumably be distributed evenly across the arms of the trial. Sixteen studies described the characteristics of patients lost during follow-up [7, [18] [19] [20] [21] [22] [23] [25] [26] [27] [30] [31] [32] 34, 35] .
Among studies including a control group (n=16), 12 reported data on adherence [18, 19, 21, [24] [25] [26] [27] [28] [30] [31] [32] 35] . In studies where adherence was defined as percentage of patients adherent [18, 21, [24] [25] [26] [27] [28] 30, 31, 35] , the adherence ranged from 46 to 92 % with the intervention while in the control group it varied from 28 to 87 %. Nine studies showed a statistically significant (P=0.05) improvement in medication adherence by the intervention compared to the control group [18, 19, 21, 25, 26, 28, [30] [31] [32] . Clowes et al. [18] showed that patients receiving feedback information in response to therapy based on bone turnover marker measurements experienced an improved adherence. Monitoring increased cumulative adherence in this study by 57 % compared with no monitoring (P=0.004). Patient education and information were found to have a significant impact on medication adherence in two small studies [19, 21] , but this result was not confirmed by two large-scale randomized studies [24, 35] . The use of a decision aid had a significant impact on the number of adherent patients (23 patients vs. 14 patients, P=0.009) [32] , and pharmaceutical care was shown to improve adherence in two studies [28, 31] although, in one of these, a significant improvement was only found using self-report questionnaire and not using pill count [31] . The simplification of dosing regimens was shown to significantly influence medication adherence. Cooper et al. showed that once-monthly ibandronate treatment plus a patient support program significantly increased medication adherence compared to once-weekly alendronate [25] , while a subcutaneous injection of denosumab every 6 months was shown to significantly improve adherence compared with weekly oral alendronate [26, 30] . Among the 13 studies assessing the impact of intervention on persistence [18, 20, [24] [25] [26] [29] [30] [31] [32] [33] [34] [35] [36] , only five showed a positive impact of the intervention [25, 26, 29, 30, 36] . Simplification of dosing regimens was found to have a significant impact on medication persistence [25, 26, 30] . Patients were most persistent with those having the least frequent dosing regimens. Electronic prescription also increased persistence with calcium (57 vs. 22 %, study vs. control groups, P=0.001) [29] and education by pharmacists increased calcium intake at 4 months (30 vs. 19 %, study vs. control groups, P=0.011). None of the four studies assessing monitoring/supervision intervention showed an impact on persistence [18, 20, 33, 34] , and most education programs had no significant impact on persistence [24, 31, 35] , including the patient support program [32] .
The quality of the studies was variable with an average quality score of 74 % (range from 50 to 93 %). Improved quality scores were obtained in more recent studies with an average quality score increasing from 66 to 80 % for studies published before and after 2010, respectively.
Discussion
We reviewed studies that assessed interventions designed to enhance patient adherence and persistence to osteoporosis medications. This study considered new interventions to previous reviews [15] . Some of these provided further evidence on the impact of patient education and monitoring/supervision on medication adherence while others tested new interventions or programs. From our update, it emerged that the efficacy of patient education is still uncertain. Nielsen et al. [21] reported an improvement in adherence, but a large-scale randomized trial found no statistically significant improvement in adherence of a telephonic motivational interviewing intervention [35] . A large well-conducted RCT is definitive within the study context, but perhaps not generalizable to all forms of education. Other studies [33, 34] confirmed that monitoring and providing feedback to patients on bone marker results is not an effective way to enhance persistence and adherence. New interventions being tested suggested that less frequent dosing regimens [26, 30] , electronic prescription [29] , and patient decision aids to facilitate decision making by describing the available options [32] could be effective patient-focused intervention to improve adherence and persistence. NR not reported,
RR relative risk
The existing literature on interventions to improve patient adherence and persistence has several limitations. First, studies were of limited quality-only 15 studies were randomized trials and only one of the studies was a double-blinded trial. While an improvement in the quality of studies was observed over time, well-designed randomized controlled trials are needed to assess the efficacy of enhancing adherence to osteoporosis medications. We acknowledge, however, that conducting a doubled-blind trial for testing an intervention for improving adherence and persistence may be difficult and sometimes impossible (e.g., blinding participants to an educational intervention). However, the use of cluster randomized controlled trials could be one way to mitigate specific methodological constraints. Second, the definitions and measurement of medication adherence and persistence were inconsistent, precluding any quantitative synthesis of the evidence. The International Society for Pharmacoeconomics & Outcomes Research (ISPOR) has previously provided guidance on how to conduct research on medication adherence using both retrospective and prospective designs [37, 38] . A new taxonomy for describing and defining adherence to medications was also recently published by the ABC project team [39] , which may facilitate standardization of future research. Adherence to medication is defined as "the process by which patients take their medication as prescribed" and persistence to medication as "the time from initiation until discontinuation" [39] . Third, information reported by authors of each article was limited. Where mean adherence scores were provided for RCTs, no information was available on the standard deviations, making it difficult to calculate a standardized effect size, which could be used as a comparative measure across studies. There was limited information reported on specific relevant points including the extent of patient co-payments and setting of care (i.e., at research centers or within the community). Fourth, no studies examined the impact of the interventions on clinical outcomes. Although testing for efficacy using proxy outcomes (e.g., adherence) is informative, it would also be appropriate for future studies to assess clinical outcomes (e.g., fractures) alongside persistence and adherence. Finally, the durability of intervention effect and appropriate period of follow-up are important considerations which are largely overlooked. Osteoporosis is a chronic disease requiring long-term treatment. A single intervention is unlikely to yield anything more than transient improvements in adherence. Increased treatment effectiveness is most probable with repeated administration of interventions and can only be demonstrated with long-term follow-up of patients, greater than 1 year.
Problems with internal and external validity of the presented data, and potential biases, could also limit the usefulness of some studies. Non-randomized uncontrolled trials [17, 19, 22, 23, 28] are prone to non-equivalent patient characteristics at the beginning of the study and differential rates of patient drop-out during follow-up. This reduces internal validity, as does the confounding effect of time in studies that adopt a pre-post group research design. External validity could also be uncertain since samples may not be wholly representative of populations with osteoporosis [17] . Measurement bias may also have occurred in those studies that used only measures of self-report to determine adherence [21, 22, 27] . It could also occur in those studies where there was lack of blinding between the data analysts and treatment groups involved. Lack of appropriate training of staff in the use of tools could lead to an undermining of the interventions' fidelity.
There were potential issues in relation to the methodology and execution of the review. While only one person conducted the literature search, it was undertaken as comprehensively as possible using multiple search terms, increasing confidence that all relevant studies were identified. The quality score was used to ensure consistency in the way we evaluated papers, with only a few discrepancies observed between reviewers which were only a matter of interpretation. Since the interventions varied across studies, we presented the information by study and by broad intervention category. So, if an intervention was focused on educating patients using different tools, we did not focus on the tools; we grouped them as "educational intervention." Adherence is a multifactorial problem, and therefore, there is no single intervention that works across different individuals' needs. We proposed to compare different intervention types and try to identify if there were clear differences among them. We would expect to update our review when new relevant interventions become available, especially with advances in telehealth technology and social media.
In summary, this review indicates that several interventions (simplification of dosing regimens, electronic prescription, patient decision aids, or patient education) may improve adherence and persistence to medicines for osteoporosis, although there were variations in the quality of studies. Of the largest and least biased studies, patient education showed, however, only marginal improvement in medication adherence and persistence, while monitoring/supervision seems ineffective in enhancing medication adherence. To demonstrate the societal benefits of adherence improvement, we recommend that the most promising interventions are subjected to rigorous evaluation of clinical effectiveness in pragmatically designed, randomized, controlled trials. It may be necessary to target interventions to specific causes of nonadherence, in an approach consistent with personalized medicine, in acknowledgment that the average effect from trials masks some patients who are very responsive to interventions. Did the analysis include an intention-to-treat analysis?
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